Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History PTGX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics PTGX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Protagonist Therapeutics Inc

PTGX
Current price
55.23 USD +1.99 USD (+3.74%)
Last closed 53.00 USD
ISIN US74366E1029
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 307 695 616 USD
Yield for 12 month +50.29 %
1Y
3Y
5Y
10Y
15Y
PTGX
21.11.2021 - 28.11.2021

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. Address: 7707 Gateway Boulevard, Newark, CA, United States, 94560

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

69.00 USD

P/E Ratio

67.72

Dividend Yield

Financials PTGX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures PTGX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+434 433 000 USD

Last Year

+60 000 000 USD

Current Quarter

+28 321 000 USD

Last Quarter

+170 638 000 USD

Current Year

+431 470 000 USD

Last Year

+60 000 000 USD

Current Quarter

+28 321 000 USD

Last Quarter

+170 034 000 USD
EBITDA 28 053 000 USD
Operating Margin TTM -68.18 %
Price to Earnings 67.72
Return On Assets TTM 2.48 %
PEG Ratio
Return On Equity TTM 8.99 %
Wall Street Target Price 69.00 USD
Revenue TTM 207 800 992 USD
Book Value 11.13 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -88.90 %
Dividend Yield
Gross Profit TTM 207 800 992 USD
Earnings per share 0.78 USD
Diluted Eps TTM 0.78 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY 351.30 %
Profit Margin 27.04 %

Stock Valuation PTGX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 67.72
Forward PE 26.39
Enterprise Value Revenue 12.89
Price Sales TTM 15.92
Enterprise Value EBITDA 88.91
Price Book MRQ 4.70

Technical Indicators PTGX

For 52 Weeks

32.50 USD 60.60 USD
50 Day MA 49.59 USD
Shares Short Prior Month 5 913 322
200 Day MA 44.79 USD
Short Ratio 6.93
Shares Short 6 731 615
Short Percent 11.45 %